Skip to Content
Upcoming Webinar

Introducing a Therapeutic Option in Relapsed/Refractory AML/ALL

Date: August 24, 2026 | 2:00 PM

 

 

 

In this session, Shrina Duggal, PharmD, BCOP (University of Pittsburgh Medical Center), will discuss the unmet need in relapsed or refractory acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), review the clinical profile of a therapeutic option and bring the evidence into practice through case-based discussion.

You’ll learn about:

  • The unmet need in relapsed or refractory acute leukemia
  • The clinical profile of a therapeutic option for relapsed or refractory acute leukemi
  • How clinical evidence can help inform real-world practice through case-based discussion

 

For additional information or login assistance, reach out to NCODA’s Jonathan Rivera.